Stocktoria
uniQure N.V. QURE
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-02-05
Chart by TradingView
4/9
Piotroski F — financial health
-1.71
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Valuation · market cap as of 2026-06-29
Market cap$3.0B
P / B14.9×
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $16.1M | $27.1M | $15.8M | $106.5M | $524.0M |
| Operating income | -$185.3M | -$184.3M | -$282.9M | -$143.2M | $310.6M |
| Net income | -$199.0M | -$239.6M | -$308.5M | — | — |
| Operating cash flow | -$178.0M | -$182.7M | -$145.9M | -$145.1M | $288.0M |
| Free cash flow | -$178.4M | -$186.1M | -$153.1M | -$162.7M | $270.5M |
| Total assets | $824.9M | $556.5M | $831.7M | $705.0M | $809.2M |
| Total liabilities | $626.0M | $563.3M | $624.0M | $229.0M | $213.4M |
| Shareholders' equity | $198.9M | -$6.8M | $207.7M | $476.0M | $595.8M |
| Ratios | |||||
| Operating margin | -1151.4% | -679.6% | -1785.5% | -134.4% | 59.3% |
| Net margin | -1236.0% | -883.4% | -1947.1% | — | — |
| FCF margin | -1108.2% | -686.2% | -966.3% | -152.8% | 51.6% |
| Return on assets | -24.1% | -43.0% | -37.1% | — | — |
| Return on equity | -100.0% | 3547.9% | -148.5% | — | — |
| Debt / equity | 0.25× | -7.60× | 0.49× | 0.22× | 0.17× |
| Current ratio | 10.43 | 9.74 | 8.85 | 6.28 | 17.09 |
| Revenue growth | -40.6% | 71.2% | -85.1% | -79.7% | 1296.8% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -1.71 (distress)
- Working capital / assets 0.719
- Retained earnings / assets -1.611
- EBIT / assets -0.225
- Equity / liabilities 0.318
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001590560 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.